No Data
No Data
The Returns On Capital At Longmaster Information & Technology (SZSE:300288) Don't Inspire Confidence
guiyang longmaster information & technology (300288.SZ): As of the end of the third quarter of this year, the "39AI General Practitioner" has not yet brought direct revenue to the company.
Longma Information (300288.SZ) stated on the investor interactive platform on November 8 that, in addition to launching the "39AI General Practitioner" mini-program (beta version), the company is currently integrating with its existing business model. Through the 39 Health-IPTV Smart Home Medical platform, it has opened TV service entry points in some provinces and cities with telecom operators. It has also integrated services into smart speakers such as Xiao Du, Xiaomi, and some models of Great Wall Motor vehicles. Users can communicate with the 39AI doctors through voice. The company continues to actively explore various collaboration methods and specific business models with medical institutions, medical experts, pharmaceutical companies, and other internet-related companies.
Langma Information: Report for the third quarter of 2024
Guiyang Longmaster Information & Technology (300288.SZ) plans to distribute a dividend of 0.1 yuan per 10 shares, with ex-rights and ex-dividends on October 21st.
guiyang longmaster information & technology (300288.SZ) announced that the company's proposed mid-term equity distribution for 2024: 0 per 10 shares...
Longmaster Information & Technology Co., Ltd.'s (SZSE:300288) Shares Climb 30% But Its Business Is Yet to Catch Up
Guiyang Longmaster Information & Technology (300288.SZ): The company has not engaged in stem cell business.
Longmaster Information (300288.SZ) stated on the investor interaction platform on September 20th that the company does not engage in stem cell business, and Guiyang Liuyi, its subsidiary, currently has no plans to introduce strategic investors. The company's "39AI General Practitioner" has begun actively exploring the commercial landing form of the product, and the company will fulfill its disclosure obligations in a timely manner according to the progress of the product. Regarding the impairment of goodwill, the company will conduct impairment tests on goodwill at the end of each year, and the test results will be based on the relevant reports or opinions of intermediary institutions such as the company's annual audit accountants and assessors.
No Data
No Data